ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ベポタスチンベシル酸塩

Bepotastine Besilate

HCID 164521
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
190786-44-8
標準SMILES
O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1
InChIKey
UDGHXQPQKQPSBB-BOXHHOBZSA-N
分子式
C27H31ClN2O6S
平均分子量
547.1 g/mol
単同位体質量
546.15913539

概要

Bepotastine besylate is an organosulfonate salt obtained by combining equimolar amounts of bepotastine and benzenesulfonic acid. A topical, selective and non-sedating histamine (H1) receptor antagonist used for treatment of itching associated with allergic conjunctivitis. It has a role as a H1-receptor antagonist and an anti-allergic agent. It contains a bepotastine(1+).

名称と識別子

優先名称
Bepotastine Besilate
IUPAC
benzenesulfonic acid;4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
現地名
ベポタスチンベシル酸塩
英語名
BEPOTASTINE BESILATE
分子式
C27H31ClN2O6S
分子量
547.06

名称と別名

Bepotastine besilate190786-44-8Bepotastine besylateBepreveTalionBepotastine benzenesulfonateBepotastine Benzenesulfonate Salt6W18MO1QR3CHEBI:31281DTXSID801725771-Piperidinebutanoic acid, 4-[(S)-(4-chlorophenyl)-2-pyridinylmethoxy]-, benzenesulfonate (1:1)1-Piperidinebutanoic acid, 4-((S)-(4-chlorophenyl)-2-pyridinylmethoxy)-, benzenesulfonate (1:1)
名称をさらに表示
ベポタスチンベシル酸塩ベポタスチンベシル酸塩 (JP17)ベトタスチンベシラートベシル酸ベポタスチン4-[4-[[(S)-α-(2-ピリジニル)-4-クロロベンジル]オキシ]ピペリジン-1-イル]ブタン酸・ベンゼンスルホン酸塩ベポタスチンベシラートタリオンタリオン-ODベシル酸ベトタスチン4-[4-[(S)-(4-クロロフェニル)(2-ピリジニル)メトキシ]ピペリジノ]酪酸・ベンゼンスルホン酸4-[4-[(S)-4-クロロ-α-(2-ピリジル)ベンジルオキシ]ピペリジノ]酪酸・ベンゼンスルホン酸BBCS-645CS-487TAU 284Talion (TN)BenzestatineBetastine besylate
RefChem:567016DTXCID3095068Bepotastine Besilate Ophthalmic Solution 1.5%(S)-4-(4-((4-Chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid monobenzenesulfonateBetotastine besilate(S)-4-(4-((4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid compound with benzenesulfonic acid (1:1)MFCD01938491Bepotastine besylate [USAN]

物性

構造計算による物性

極性表面積
125 Ų
水素結合供与体数
2
水素結合受容体数
8
回転可能結合数
9
重原子数
37
形式電荷
0
複雑度
632

実験および物理化学的性質

Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Anti-Allergic Agents; Antihistamines

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

物理化学的性質

融点
161 · 161-163°
比旋光度
20 · D20 +6.0° (c = 5 in methanol)
貯蔵温度
Inert atmosphere,Room Temperature
溶解性
DMSO(微加熱)、メタノール(微加熱)
外見
個体
色
ホワイトからライトベージュ
安定性
吸湿性
InChIKey
UDGHXQPQKQPSBB-ZMBIFBSDSA-N
SMILES
[S](=O)(=O)(O)c4ccccc4.Clc1ccc(cc1)[C@@H](OC3CCN(CC3)CCCC(=O)O)c2ncccc2

化学的性質

化学的特性Off-White to Light Beige Solid

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 33.3% (1 of 3) of reports.

Warning

H361 (33.3%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesRepr. 2 (33.3%)

毒性情報

Exposure Routes · 1 件

Oral, Ophthalmic. Tmax, after single dose, opthalmic = 1.2 hours; Cmax, 1.5%, opthalmic dose = 7.3 ± 1.9 ng/mL; After 24 hours post-installation, levels of bepotastine are below quantifiable limit of 2 ng/mL. Minimal systemic absorption with opthalmic dosage form.

Toxicity Summary · 1 件

Because of a type 1 hypersensitivity reaction cascade that is triggered by antigen exposure, allergic conjunctivitis occurs. Allergen exposure is followed by conjunctival mast cell degranulation and histamine released as a result of the formation of complementary IgE cross-links on the conjunctiva. Due to the release of histamine, symptoms such as itching can be observed. Bepotastine works to relieve itchy eyes by three primary mechanisms of action. It is a non-sedating, selective antagonist of the histamine 1 (H1) receptor, a mast cell stabilizer, and it suppresses the migration of eosinophils into inflamed tissues to prevent tissue damage and worsening of allergic inflammation of the conjunctiva.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

化学と産業

薬理情報

Metabolism/MetabolitesMinimal metabolism via CYP enzymes Route of Elimination: When a oral dose of 2.5 - 40 mg bepotastine is given, 75%-90% of the dose was excreted unchanged in the urine by 24 hours. Half Life: Elimination half life = 2.5 hours
FDA Pharmacological Classification · 4 件

BEPOTASTINE BESILATE

Histamine-1 Receptor Antagonist [EPC]

BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5%

Histamine-1 Receptor Antagonist [EPC]

MeSH Pharmacological Classification · 1 件

Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)

用途と製造

UsesFor the symptomatic treatment of itchy eyes (caused by IgE-induced mast cell degranulation) due to allergic conjunctivitis. Used in the treatment of allergic rhinitis and uriticaria/puritus. [Wikipedia]
応用分野 · 3 件

用途ヒスタミン H1 受容体の阻害 作用を介して、抗アレルギー作用を示します。

説明Betotastine was introduced in Japan for the treatment of allergic rhinitis. This structurally-related derivative of chlorpheniramine and ebastine is prepared by condensation of optically-resolved 4-[1-(4-chlorophenyl)-1-(2-pyridyl)-methoxy]piperidine with ethyl 4-bromobutyrate followed by ester hydrolysis. Betotastine is the seventh marketed non-sedating histamine H1 antagonist. Its very low sedative side effect is due to very poor penetration in the central nervous system. Besides its potent and long-acting activity in models of allergic rhinitis, betotastine was also shown to act as a PAF antagonist and inhibit LTD4 in tracheal smooth muscle and ileum, IL-5 production by human peripheral blood mononuclear cells as well as eosinophil infiltration in the airway and peripheral blood. As a consequence, it is currently being developed against other allergic and respiratory disorders.

関連反応

3 件
反応記録を作成
HRID 381669 の反応式
HRID 381669生成物として
HRID 1180648 の反応式
HRID 1180648生成物として
HRID 1837027 の反応式
HRID 1837027生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
190786-44-8
PubChem CID
164521
DTXSID
DTXSID80172577
ChEMBL
CHEMBL1201759
ChEBI
CHEBI:31281
UNII
6W18MO1QR3
EC Number
878-395-1
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
WGK 3
Hazard Classifications
Repr. 2
ストレージクラス
11 - Combustible Solids

使用Bepotastine is a non-sedating, selective antagonist of histamine 1 (H1) receptor with pIC50 of 5.7

上流・下流製品情報

上流原料

Phosphonic acid,(3-methyl-2-oxo-5-heptynyl)-, dimethyl ester塩化スルフィニルBenzofurancarboxylic acid炭酸水素ナトリウム水素化リチウムアルミニウムナトリウムメトキシド塩化セリウム(Ⅲ)七水和物p-トルエンスルホン酸一水和物
補足説明 · 1 件

定義ChEBI: An organosulfonate salt obtained by combining equimolar amounts of bepotastine and benzenesulfonic acid. A topical, selective and non-sedating histamine (H1) receptor antagonist used for treatment of itching associated with allergic co junctivitis.